Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Stem Cell Culture

Stem Cell Culture

Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...

Adult Stem Cells

Adult Stem Cells

Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously renew...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Embryonic Stem Cells

Embryonic Stem Cells

Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...

Embryonic Stem Cells

Embryonic Stem Cells

Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial.

ESMO gastrointestinal oncology·2026

Same author

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

Journal for immunotherapy of cancer·2019

Same author

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018

Same author

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

The British journal of dermatology·2018

Same author

X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.

Cell death & disease·2016

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Published on: March 30, 2018

Technology evaluation: Stem-cell therapy, Aastrom Biosciences Inc.

¹Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. morse004@mc.duke.edu

Current Opinion in Molecular Therapeutics

|July 25, 2009

Summary

This summary is machine-generated.

The AastromReplicell System expands hematopoietic stem cells for transplantation, addressing limitations of traditional methods. This automated system shows promise for generating sufficient cells and reducing tumor contamination.

More Related Videos

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

Published on: January 4, 2015

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

Related Experiment Videos

Last Updated: Jun 21, 2026

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Published on: March 30, 2018

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

Published on: January 4, 2015

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

Area of Science:

Stem cell biology
Hematopoiesis
Cellular therapy

Background:

Traditional stem cell transplantation relies on large-volume bone marrow or peripheral blood harvests.
Existing methods face challenges including insufficient cell numbers and tumor cell contamination.
Gene transfer efficiency is limited in traditional stem cell products due to low progenitor cell proliferation.

Purpose of the Study:

To evaluate the AastromReplicell System, a closed, automated platform for hematopoietic cell expansion.
To determine optimal conditions for hematopoietic cell growth within the AastromReplicell System.
To assess the system's potential for generating sufficient cells for hematopoiesis reconstitution and reducing tumor contamination.

Main Methods:

Utilized unpurified bone marrow or cord blood mononuclear cells.
Employed high cell densities and serum-containing medium.
Investigated specific plastic surface types for optimal cell culture.

Main Results:

Established optimal growth conditions for hematopoietic cells in the AastromReplicell System.
Demonstrated the feasibility of generating adequate cell numbers for hematopoiesis reconstitution from limited progenitor volumes.
Observed a passive decrease in tumor cell contamination during the culture period.

Conclusions:

The AastromReplicell System offers a viable automated approach for expanding hematopoietic stem cells.
The system addresses key limitations of traditional stem cell transplantation, including cell yield and tumor contamination.
Further direct comparative studies are needed to confirm superior efficacy and cost-effectiveness compared to conventional methods.